病毒学报

参考文献

[1] Zhu N,Zhang D Y,Wang W L,Li X W,Yang B,Song J D,Zhao X,Huang B Y,Shi W F,Lu R J,Niu P H,Zhan F X,Ma X J,Wang D Y,Xu W B,Wu G Z,Gao G F,Tan W J. A Novel Coronavirus from Patients with Pneumonia in China,2019[J].N Engl J Med,2020[DB/OL].DOI:10.1056/NEJMoa2001017.

[2] Chen Y, Liu Q, Guo D. coronaviruses:genome structure,replication,and pathogenesis[J].J Med Virol,2020[DB/OL].DOI:10.1002/jmv.25681.

[3] Chen Y,Guo D. Molecular mechanisms of coronavirus RNA capping and methylation[J]. Virol Sin,2016,31(1):3-11.

[4] Cui J,Li F,Shi Z L.Origin and evolution of pathogenic coronaviruses[J]. Nat Rev Microbiol,2019,17(3):181-192.

[5] World Health Organization:Clinical management of severe acute respiratory infection when Novel coronavirus(nCoV)infection is suspected:Interim Guidance.2020[DB/OL].

[6] Xu X T,Chen P,Wang J F,Feng J N,Zhou H,Li X,Zhong W,Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[DB/OL].https：//doi.org/10.1007/s11427-020-1637-5. Sci China Life Sci,2020

[7] Nukoolkarn V,Lee V S,Malaisree M,Aruksakulwong O,Hannongbuac S. Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV3CLpro inhibitors[J]. J Theor Biol,2008,254(4):861-867.

[8]江华，邓洪飞，王宇，刘展，孙明伟.洛匹那韦/利托那韦（LPV/r）用于2019新型冠状病毒肺炎的治疗可能性：基于既往冠状病毒肺炎研究的快速系统评价[J]中华急诊医学杂志，2020,29(2):182-186.

[9] Chu M C,Cheng V C C,Hung I F N,Wong M M L,Chan K H,Chan K S,Kao R Y T,Poon L L M,Wong C L P,Guan Y,Peiris J S M,Yuen K Y.Role of lopinavir/ritonavir in the treatment of SARS:initial virological and clinical findings[J]. Thorax,2004,59(3):252-256.

[10]De Wilde A H,Jochmans D,Posthuma C C,Jessika C.Zevenhoven-Dobbe,Nieuwkoop S V,Bestebroer T M,Bernadette G. van den Hoogen,Neyts J,Snijder E J.Screening of an FDA-Approved compound library identifies four small-Molecule Inhibitors of Middle East Respiratory Syndrome coronavirus replication in cell culture[J]. Antimicrob Agents Ch,2014,58(8):4875-4884.

[11]Que T L,Wong V C W,Yuen K Y. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir:a multicentre retrospective matched cohort study[J]. Hong Kong Med J,2003,9(6):399-406.

[12]Chan J F W,Yao Y,Yeung M L,Deng W,Bao L L,Jia L L,Li F D,Xiao C,Gao H,Yu P,Cai J P,Chu H,Zhou J,Chen H L,Qin C,Yuen K Y. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a non-human primate model of common marmoset[J]. The J Inf Dis,2015,212(12):1904-1913.

[13]Arabi Y M,Asiri A Y,Assiri A M. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b(MIRACLE trial):statistical analysis plan for a recursive two-stage group sequential randomized controlled trial[J]. Trials,2020,21(1):1-8.

[14]Stockman L J,Bellamy R,Garner P. SARS:Systematic Review of Treatment Effects[J/OL]. PLoS Med,2006,3(9):e343.

[15]Haagmans B L,Kuiken T,Martina B E,Fouchier R A M,Rimmelzwaan G F,Amerongen G V,Riel D V,Jong T D,Itamura S,Chan K H,Tashiro M T,Osterhaus A D M E. Pegylated interferon-αprotects type 1pneumocytes against SARS coronavirus infection in macaques[J]. Nat Med,2004,10(3):290-293.

[16]Hart B J,Dyall J,Postnikova E,Zhou H,Kindrachuk J,Johnson R F,Olinger G G,Frieman M B,Holbrook M R, Jahrling P B, Hensley L. Interferon-βand mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays[J]. J Gen Virol,2014,95(Pt_3):571-577.

[17]Adedeji A O,Sarafianos S G. Antiviral drugs specific for coronaviruses in preclinical development[J]. Curr Opin Virol,2014,8:45-53.

[18]Zhao,Z. Description and clinical treatment of an early outbreak of severe acute respirator syndrome(SARS)in Guangzhou,PR China[J]. J Med Microbiol,2003,52(8):715-720.

[19]Loutfy M R,Blatt L M,Siminovitch K A,Ward S,Wolff B B,Lho H,Pham D H,Deif H,LaMere E A,Chang M,Kain K C,Farcas G A,Ferguson P,Latchford M,BSc,Levy G,Dennis J W,Lai E K Y,Fish E N.Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome:a preliminary study[J]. JAMA,2003,290(24):3222-3228.

[20]Al-Tawfiq J A,Momattin H,Dib J,Memish Z A.Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus:an observational study[J]. Int J Infect Dis,2014,20:42-46.

[21]Omrani A S,Saad M M,Baig K,Bahloul A,AbdulMatin M,Alaidaroos A Y,Almakhlafi G A,Albarrak M M,Memish Z A,Albarrak A M. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection:a retrospective cohort study[J].Lancet Infect Dis,2015,14(11):1090-1095.

[22]Shalhoub S,Farahat F,Al-Jiffri A,Simhairi R,Shamma O,Siddiqi N,Mushtaq A. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia:a retrospective study[J]. J Antimicrob Chemoth,2015,70(7):2129-2132.

[23]Cinatl J,Morgenstern B,Bauer G,Chandra P,Rabenau H,Doerr H. Treatment of SARS with human interferons[J]. Lancet(North American Edition),2003,362(9380):0-294.

[24]Chan J F,Chan K H,Kao R Y,To K K,Zheng B J,Li C P,Li P T,Dai J,Mok F K,Chen H,Hayden F G,Yuen K Y. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus[J]. J Infect,2013,67(6):606-616.

[25]Blaising J,Lévy P L,Polyak S J,Stanifer M,Boulant S,Pécheur E I. Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking[J]. Antivir Res,2013,100(1):215-219.

[26]Blaising J,Polyak S J,Pécheur E I. Arbidol as a broadspectrum antiviral:An update[J]. Antivir Res,2014,107:84-94.

[27]Shi L,Xiong H,He J,Deng H,Li Q,Zhong Q,Hou Q,Cheng L,Xiao H,Yang Z. Antiviral activity of arbidol against influenza A virus,respiratory syncytial virus,rhinovirus,coxsackie virus and adenovirusin vitroandin vivo[J]. Arch Virol,2007,152(8):1447-1455.

[28]纪晓光，赵艳红，张敏.阿比多尔抗SARS病毒的体外实验研究[J].解放军药学学报，2004(4):274-276.

[29]关文达，杜秋伶，江海明，赵金存，杨子峰.阿比多尔与连花清瘟胶囊对中东呼吸综合征冠状病毒的体内外抑制作用比较[J].广东医学，2018,039(023):3454-3458.

[30]Marano G,Vaglio S,Pupella S,Facco C,Catalano L,Liumbruno G M,Grazzini G. Convalescent plasma:new evidence for an old therapeutic tool?[J]. Blood Transfusion,2016,14(2):152.

[31]Mair-Jenkins J,Saavedra-Campos M,Baillie J K,Cleary P,Khaw F M,Lim W S,Makki S,Rooney K D,Nguyen-Van-Tam J S,Beck C R. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology:a systematic review and exploratory metaanalysis[J]. The J Infect Dis,2015,211(1):80-90.

[32]Arabi Y M,Fowler R,Balkhy H H. Proceedings of the Middle East Respiratory Syndrome(MERS)Coronavirus research initiative workshop,September 9–10 2015 in Riyadh,KSA[J]. J Infect and Public Heal,2016:S187603411630017X.

[33]Griensven J V,Edwards T,Lamballerie X D,Semple M G, Gallian P, Baize S, Horby P W, Raoul H,Magassouba N,Antierens A,Lomas C,Faye O,Sall A A,Fransen K,Buyze J,Ravinetto R,Tiberghien P,Claeys Y,Crop M D,Lynen L,Bah E I,Smith P G,Delamou A,Weggheleire A D,Haba N. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea[J]. N Engl J Med,2016,374(1):33-42.

[34]Luke T,Wu H,Zhao J,Channappanavar R,Coleman C M,Jiao J A,Matsushita H,Liu Y,Postnikova E N,Ork B L,Glenn G,Flyer D,Defang G,Raviprakash K,Kochel T,Wang J,Nie W,Smith G,Hensley L E,Olinger G G,Kuhn J H,Holbrook M R,Johnson R F,Perlman S,Sullivan E,Frieman M B.Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo[J]. Sci Transl Med,2016,8(326):326ra21-326ra21.

[35]Beigel J H,Voell J,Kumar P,Raviprakash K,Wu H,Jiao JA,Sullivan E,Luke T,Davey R T J. Safety and tolerability of a novel,polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle:a phase 1 randomised,double-blind,single-doseescalation study[J]. Lancet Infect Dis,2018,18(4):410-418.

[36]陈顺达，杨洋，郭洁茹.中东呼吸综合征治疗药物研究进展[J].药物流行病学杂志，2016,(9):586-590.

[37]Tian X L,Li C,Huang A L,Xia S A,Lu S C,Shi Z L,Lu L,Jiang S B,Yang Z L,Wu Y L,Ying T L. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody[J]. bioRxiv, 2020[DB/OL]. doi. 10.1101/2020.01.28.923011.

[38]Li Y,Zhang J,Wang N,Li H B,Shi Y,Guo G,Liu K Y,Zeng H,Zou QM. Therapeutic Drugs Targeting 2019-nCoV main protease by high-throughput screening[J].bioRxiv,2020[DB/OL]. doi:http：//dx. doi. org/10.1101/2020.01.28.922922.

[39]Liu X,Wang X J. Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines[J]. bioRxiv,2020[DB/OL].doi:http：//dx.doi.org/10.1101/2020.01.29.924100.

[40]Xu Z,Peng C,Shi Y,Zhu Z D,Mu K J,Wang X Y.Nelfinavir was predicted to be a potential inhibitor of2019-nCov main protease by an integrative approach combining homology modelling,molecular docking and binding free energy calculation[J]. bioRxiv,2020[DB/OL].doi:https：//doi.org/10.1101/2020.01.27.921627.

[41]Morse J S,Lalonde T,Xu S,Liu W S. Learning from the past:Possible urgent prevention and treatment options for severe acute respiratory infections caused by2019-nCoV[J]. 2020[DB/OL]. https：//doi. org/10.26434/chemrxiv.11728983.v1.

[42]Brown A J,Won J J,Graham R L,Dinnon III K H,Sims A C,Feng J Y,Cihlar T,Denison M R,Baric R S,Sheahan T P. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase[J]. Antivir Res,2019,169:104541.

[43]Jordan P C,Stevens S K,Deval J. Nucleosides for the treatment of respiratory RNA virus infections[J].Antivir Chem Chemoth,2018,26:2040206618764483.

[44]Sheahan T P,Sims A C,Leist S R,Sch?fer A,Won J,Brown A J,Montgomery S A,Hogg A,Babusis D,Clarke M O,Spahn J E,Bauer L,Sellers S,Porter D,Feng J Y,Cihlar T,Jordan R,Denison M R,Baric R S.Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV[J]. Nat Commun,2020,11(1):1-14.